Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method-Reference-Cited by-同舟云学术

Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method

Published:2021-09-01 Issue:9 Volume:44 Page:1202-1209
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Oyama Takuji¹,Kamata Shotaro²,Ishii Isao²,Miyachi Hiroyuki³

Affiliation:

1. Faculty of Life and Environmental Sciences, University of Yamanashi

2. Laboratory of Health Chemistry, Showa Pharmaceutical University

3. Lead Exploration Unit, Drug Discovery Initiative, The University of Tokyo

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/44/9/44_b21-00220/_pdf

Reference31 articles.

1. 1) Dubois V, Eeckhoute J, Lefebvre P, Staels B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J. Clin. Invest., 127, 1202–1214 (2017).

2. 2) Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature, 395, 137–143 (1998).

3. 3) Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW. Structural basis for the activation of PPARγ by oxidized fatty acids. Nat. Struct. Mol. Biol., 15, 924–931 (2008).

4. 4) Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K. Structural insight into PPARγ activation through covalent modification with endogenous fatty acids. J. Mol. Biol., 385, 188–199 (2009).

5. 5) Franssen R, Vergeer M, Stroes ESG, Kastelein JJP. Combination statin-fibrate therapy: safety aspects. Diabetes Obes. Metab., 11, 89–94 (2009).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virtual Screening of 5-Benzylthiazolidine-2,4-Dione Derivatives in Search of Potent Ppar-Gamma Agonist;2024

2. Attempt to Create a Drug for Treatment of Fibrotic Diseases Based on the Non-genomic Action of Nuclear Receptors;YAKUGAKU ZASSHI;2022-12-01

3. Toward High-throughput Crystal Structure Determination of PPAR Ligand-binding Domains in Complexes with Less Soluble Ligands;YAKUGAKU ZASSHI;2022-12-01

4. Arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists covalently bind to the PPARγ ligand binding domain with a unique binding mode;Bioorganic & Medicinal Chemistry Letters;2022-05

5. Crystal structures of the ligand-binding domain of human peroxisome proliferator-activated receptor δ in complexes with phenylpropanoic acid derivatives and a pyridine carboxylic acid derivative;Acta Crystallographica Section F Structural Biology Communications;2022-01-31